Authors: Cristina Gervasoni Roberta Terzi Marco Heidempergher Emilio Clementi Dario Cattaneo
Publish Date: 2015/01/22
Volume: 71, Issue: 3, Pages: 383-385
Abstract
Emerging evidence shows that patients with renal dysfunction or on haemodialysis treated with the conventional linezolid LZD dose 600 mg bid have higher drug exposure and higher frequency of haematological toxicity compared with patients with normal renal function 1 2 3 4 We here report the successful application of therapeutic drug monitoring TDM of LZD in a peritoneal dialysis PD patient who experienced drugrelated severe thrombocytopoenia while treated with the conventional 600 mg bid LZD dose
Keywords: